Hypertrophic cardiomyopathy – symptomatic atrial fibrillation in a patient at high risk of sudden cardiac death (RCD code: V‑2A.2)
1
2nd Department of Cardiology and Cardiovascular Interventions, University Hospital, Krakow, Poland
2
1st Department of Cardiology, Interventional Electrocardiology and
Hypertension, Jagiellonian University, Medical College, Krakow, Poland;
3
2nd Department of Cardiology, Jagiellonian University Medical College, Krakow, Poland
Received: 2018-10-17
Revised: 2019-01-10
Accepted: 2019-01-31
Published: 2019-03-05
We present the case of a young patient with significant left ventricular hypertrophy as a common representation of the hypertrophic cardiomyopathy (HCM) phenotype. The clinical presentation and diagnostic route of the disease (despite negative genotype), which can be found in everyday cardiology practice, are shown. Despite the presence of guidelines on this topic, each clinical case is demanding, especially during qualification for invasive procedures. Limited data about the periprocedural risk of catheter ablation and success rate in HCM makes physician decisions for this type of patient challenging. The importance of informed consent and how the patient’s decisions affect further progress are also shown. JRCD 2018; 4 (1): 18–21
rare disease, hypertrophic cardiomyopathy, atrial fibrillation, subcutaneous implantable cardioverter defibrillator, transcatheter ablation